Access the 4DM Demo Online!

Home > About Us > History

History of INVIA


James Corbett, MD


Dr. Corbett is the Chairman of the Board of INVIA where he is responsible for the company’s strategic direction and supervising clinical validation.


He has over 30 years of experience in nuclear cardiology, with specializations in Cardiovascular Disease and Nuclear Cardiology.


He has been at the University of Michigan Medical Center, Division of Nuclear Medicine, for 21 years, where his current appointment is as Professor of Internal Medicine, Professor of Radiology and the Director of Cardiovascular Nuclear Medicine. Prior to that  he was with the University of Texas Health Science Center for 12 years, where he moved up to the position of Director of Nuclear Cardiology.

Among his many accomplishments, Dr. Corbett is one of the founding research investigators in gated perfusion tomography, being first to develop a commercially available computer application to generate quantitative three-dimensional displays of measured heart blood flow and function. Dr. Corbett has 75 peer-reviewed writings to his credit, which were published in various scientific journals. His numerous other writings include book chapters, non-peer reviewed publications, and abstracts. These writings are predominantly in the areas of imaging heart blood flow and function as well as the cardiac autonomic nervous system.


He is well-regarded in the field of Nuclear Cardiology, and frequently invited to speak on various subjects in the field. Dr. Corbett is a regular reviewer for six medical publications, including Circulation, the Journal of American College of Cardiology, Journal of Nuclear Cardiology and the American Heart Journal. His appointments include the Board of Directors for the Society of Nuclear Medicine Cardiovascular Council; chairman of the Attenuation Correction Task Force; and chairman of the Equilibrium Radionuclide Ventriculography Imaging Guidelines Writing Group – both for the American Society of Nuclear Cardiology.


Dr. Corbett has a B.S. degree in Mechanical Engineering from the University of North Dakota, as well as an M.D. from the University of Minnesota.

Edward Ficaro, PhD


As President of INVIA, Dr. Ficaro is responsible for overall operations of the company, with a focus on the technical development of new imaging and software products.


He has more than 25 years of experience in nuclear cardiology, with a primary focus on algorithm development for modeling physiologic processes. That experience was gained through appointments at the Division of Nuclear Medicine at the University of Michigan Medical Center, initially as a Research Investigator, then and at present as Assistant Research Scientist.


He continues teaching a course in nuclear medicine, Biomedical Engineering, at the University of Michigan.

Global institutions and companies have invited Dr. Ficaro to speak on the topics of nuclear cardiology and imaging software. Since 1991, he has accepted more than 100 such speaking engagements around the world. Likewise, he has been widely published in peer-review publications, non-peer review publication, book chapters and abstracts, with over 150 such writings to his credit.


Dr. Ficaro served as a member of the American Society of Nuclear Cardiology Board of Directors and chairman for the Society’s Quality Assurance Committee from 2005 to 2008. Dr. Ficaro also served as a consultant physicist for Intersocietal Commission for the Accreditation of Nuclear Medicine Laboratories (ICANL) from 2005 to 2008.


Additionally, Dr. Ficaro is a reviewer for several nuclear medicine journals. His BS, MS degrees, and Ph.D., in Nuclear Engineering, are from the University of Michigan.


In the 1990s, James Corbett, MD and Edward Ficaro, PhD joined forces at the University of Michigan to develop and automate quantitative software for SPECT cardiac imaging. Over the years, the original product created and implemented at the  U-M Medical Center evolved. In 2005, Drs. Corbett and Ficaro founded INVIA to further develop 4DM while maintaining the same commitment to quality, accuracy, and excellence. Today, they continue to support academic and research pursuits at the University while leading a talented group of software engineers and business professionals at INVIA.












Development begins at the University of Michigan under the leadership of Dr. Corbett and Dr. Ficaro.

4DM emerges as the standard tool for nuclear cardiology interpretation at the University of Michigan Medical Center.

Siemens, GE, and Philips are participating in commercial sales.

INVIA is spun out of the University of Michigan to accelerate product development.

INVIA adds PET and CT quantification to its flagship product.

Now multi-lingual, 4DM is available in seven languages.

INVIA adds CFR and MUGA quantification.

4DM is now translated in 13 languages, has multi-monitor support, an automated workflow selector, and support for the Ammonia tracer for CFR.

4DM is now translated in 20 languages!

All new 4DM Reporting — overhauled nuclear cardiac specific reporting engine.

Inflammatory quantification is added for identifying the presence and extent of cardiac sarcoidosis.

Interested in the Full History of INVIA?

What's In a Name?





The Original Name of Corridor4DM


4DM was referred to as "3D-MSPECT" during the early development stages at the University of Michigan.


3D was representative of the volume-depicting images while MSPECT denoted myocardial and the SPECT modality.

A Fourth Dimension Was Created


The name was changed when the application added the fourth dimension - time - to its images with cine capabilites.

Slight Variation to Disinguish Modality


The name was then slightly modified to more greatly distinguish the SPECT modality.


The term "4DM" was born.

A New Name for New Era


4DM now supports PET, Coronary Flow Reserve (CFR), and CT modalites.

Scroll to

Read More

Are you a hospital or clinic looking for more information on 4DM?

Request Access to our Prospect Center.